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Abstract
The genetic mechanisms underlying adrenocortical tumor development are still largely unknown. We used high-
resolution single nucleotide polymorphism microarrays (Affymetrix SNP 6.0) to detect copy number alterations
(CNAs) and copy-neutral losses of heterozygosity (cnLOH) in 15 cortisol-secreting adrenocortical adenomas with
matched blood samples. We focused on microalterations aiming to discover new candidate genes involved in early
tumorigenesis and/or autonomous cortisol secretion. We identified 962 CNAs with a median of 18 CNAs per sam-
ple. Half of them involved noncoding regions, 89% were less than 100 kb, and 28% were found in at least two
samples. The most frequently gained regions were 5p15.33, 6q16.1, 7p22.3-22.2, 8q24.3, 9q34.2-34.3, 11p15.5,
11q11, 12q12, 16q24.3, 20p11.1-20q21.11, and Xq28 (≥20% of cases), most of them being identified in the same
three adenomas. These regions contained among others genes like NOTCH1, CYP11B2, HRAS, and IGF2. Recurrent
losses were less common and smaller than gains, being mostly localized at 1p, 6q, and 11q. Pathway analysis
revealed that Notch signaling was the most frequently altered. We identified 46 recurrent CNAs that each affected
a single gene (31 gains and 15 losses), including genes involved in steroidogenesis (CYP11B1) or tumorigenesis
(CTNNB1, EPHA7, SGK1, STIL, FHIT ). Finally, 20 small cnLOH in four cases affecting 15 known genes were found.
Our findings provide the first high-resolution genome-wide view of chromosomal changes in cortisol-secreting
adenomas and identify novel candidate genes, such as HRAS, EPHA7, and SGK1. Furthermore, they implicate that
the Notch1 signaling pathway might be involved in the molecular pathogenesis of adrenocortical tumors.
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Introduction
Adrenocortical tumors are among the most frequent human neoplasias
with an overall prevalence of 2% in the general population [1]. They
mostly consist of benign adrenocortical adenoma (ACA), whereas adre-
nocortical carcinomas (ACC) are rare aggressive tumors with a poor
prognosis [2]. The genetic mechanisms underlying adrenocortical tumor
development are still largely unknown. In particular, it is still unclear if
ACCs evolve from ACAs after a second-hit paradigm. Although such a
sequence has been occasionally observed [3], long-term follow-up of
incidentally discovered adrenocortical neoplasms suggests that ACA
in general maintain a benign phenotype [4]. Adrenocortical tumors
can be either endocrinologically silent or hormonally active. It has been
postulated that autonomous hormone production in ACA may be as-
sociated with increased expression of enzymes needed for corticosteroid
production along with alterations in transcription factors that enhance
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the expression of steroid-metabolizing enzymes [5]. However, the molec-
ular mechanisms responsible for hormone overproduction are not well
understood. Because autonomous cortisol hypersecretion is per se associ-
ated with serious morbidity and increased mortality [6], a better under-
standing of its pathogenesis might lead to new treatment strategies.
Molecular studies of the inherited syndromes with increased ACC
risk coupled with recent advances in genomic and expression profiling,
have helped to improve our understanding of the genetic mechanisms
underlying adrenocortical tumor development [7–9]. For instance,
microsatellite markers revealed common inactivating mutations or loss
of heterozygosity (LOH) at 17p13, a region that includes the TP53
tumor suppressor gene, LOH at 11q13 and 2p16, and alterations of
the imprinted 11p15 locus (paternal isodisomy) leading to IGF2 over-
expression in ACC [7,10]. In addition, a constitutive activation of the
Wnt/β-catenin signaling pathway is common in both ACA and ACC,
being likely involved in both adrenocortical development and neoplasia
[11–13]. Nevertheless, with few exceptions, the molecular candidates
so far proposed as diagnostic or prognostic markers have not been val-
idated in subsequent studies, mostly due to different methodological
approaches and heterogeneity of the tumor. Copy number alterations
(CNAs) have been described in adrenal hyperplasia, ACA and ACC
using fluorescence in situ hybridization (FISH), karyotyping, and either
conventional comparative genomic hybridization (CGH) [14–18] or
array-based CGH [19,20]. In particular, losses at 1p, 2q, 3p, 6q, 9,
11, 17p, and 18q and gains at 4, 5, 12q, 16, 19, and 20q have been
reported in patients with sporadic ACC, demonstrating large genetic
derangements, often involving previously undescribed pathomecha-
nisms [21]. However, results from CGH studies have been highly
variable and restricted to very large regions containing too many genes
to allow identification of specific candidate genes associated with disease
initiation or progression. In addition, CGH cannot detect other chro-
mosomal changes such as LOH.
Single nucleotide polymorphism (SNP) microarrays provide a use-
ful method, which allows detecting not only genome-wide copy
number (CN) data at high resolution but also LOH events [22].
Merging these two analyses, it is also possible to identify copy-neutral
LOH (cnLOH or uniparental disomy [UPD]), a previously underesti-
mated chromosomal defect which comprises 50% to 70% of LOH
events detected in human tumors [23]. Furthermore, recent SNP array
platforms, such as Affymetrix SNP 6.0, often identify amplifications/
deletions at a single gene level, which could not have been accomplished
by previous methods. Thus, modern SNP arrays offer a powerful and
increasingly popular method for oncogene and tumor suppressor gene
discovery, as well as for cancer classification [24].
In the present study, we used high-resolution SNP arrays for the
first time to investigate genetic events involved in the pathogenesis of
adrenocortical tumors. We selected benign cortisol-secreting tumors
with matched blood samples in a paired analysis approach to restrict
tissue heterogeneity and to allow improved detection of tumor spe-
cific events. Our aim was to discover new candidate genes involved in
early tumorigenesis and/or autonomous cortisol secretion.
Materials and Methods
Study Population
A total of 18 cortisol-secreting ACAs with matched normal pe-
ripheral blood samples were selected for the present study. Clinical
parameters, such as sex, age at diagnosis, date of surgery, tumor size,
pathologic classification, and results of hormone analysis were col-
lected from patient records. Specifically, baseline morning serum cor-
tisol and plasma corticotrophin levels, cortisol concentrations after
dexamethasone suppression test (1 mg, 23.00 hours), 24-hour urinary
free cortisol excretion, and midnight serum or salivary cortisol levels
were considered. Malignancy was excluded according to recognized
clinical, biochemical, and morphologic criteria. The biochemical di-
agnosis of cortisol hypersecretion was made according to established
criteria [25]. Subclinical hypercortisolism was defined according to
the following criteria: postdexamethasone cortisol levels greater than
5 μg/dl, corticotrophin levels less than 25 pg/L and at least one addi-
tional pathologic test among 24 hours urinary free cortisol and mid-
night serum or salivary cortisol levels in the absence of typical clinical
features of Cushing syndrome [26]. Clinical sequelae of cortisol excess
were also taken into account (i.e., arterial hypertension, diabetes
mellitus, and osteoporosis). The study was approved by the ethical
committee of the University of Würzburg (permit no. 93/02), and
written informed consent was obtained from all patients.
Tissue Samples and DNA Extraction
Tumor tissue specimens collected from patients operated between
1995 and 2010 were used for the present study. Corresponding pe-
ripheral blood samples were also taken from all patients. Tumor and
blood samples had been stored at −80°C in our Department (Uni-
versity Hospital, Würzburg, Germany). Genomic DNA from both
frozen tumor and blood samples was extracted using standard proce-
dures (QIAamp DNA Mini and Blood Mini; Qiagen, Valencia, CA).
Only samples with appropriate DNA quality as measured by the ratio
of absorbance at 260 to 280 nm (A260/A280 ≥ 1.8) using the Bio-
analyzer (Agilent Technologies, San Jose, CA) were further evaluated.
SNP Arrays
SNP array experiments were performed using the high-resolution
Affymetrix GeneChip Human Mapping 6.0 microarray (SNP 6.0;
Affymetrix, Inc, Santa Clara, CA) containing 906,600 probes for
SNPs and 946,000 probes for CNVs, with a median physical inter-
marker distance of 680 bp. Briefly, 250 ng of genomic DNA was
digested with NspI and StyI (New England Biolabs, Inc, Ipswich,
MA), respectively, and then ligated to Nsp or Sty adaptors. The
adaptor-ligated DNA fragments were amplified, fragmented using
DNase I, end labeled with a biotinylated nucleotide, and hybridized
to a human SNP 6.0 array (Affymetrix) at 49°C for 17 hours. After
hybridization, the arrays were washed, stained, and finally scanned
with a GeneChip Scanner 3000 7G (Affymetrix). All procedures
were performed according to the manufacturer’s protocols.
SNP Arrays Data Analysis
Affymetrix raw intensity data (.CEL files) were generated by the
command console and quality control (QC) was assessed by the
Genotyping Console software (GTYPE version 4.0; Affymetrix).
Only arrays were accepted that had a QC of 1.7 or higher and a
MAPD of 0.3 or smaller, as recommended for large study sets.
CN analysis was performed using the Partek Genomics Suite soft-
ware package, Version 6.5 (Partek GS; Partek, Inc, St. Louis, MO).
In particular, .CEL files were imported into the Partek GS and nor-
malized to baseline reference intensities using the robust multichip
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average algorithm. A preliminary unpaired data analysis was per-
formed in all 18 ACAs and 18 blood samples. Unexpectedly and
for no obvious reasons, three blood samples showed a large number
of CNAs. Similar results were obtained after repeated blood sampling,
hybridization and data analysis. Therefore, it was decided to exclude
these samples from further analysis. The paired CNA analysis was
then carried out by comparing each intensity of the hybridization sig-
nal from a tumor sample to that of the matched normal lymphocyte
DNA. A log ratio calculation was carried out to determine the relative
intensity and the log ratios were then turned into CN space using the
following formula: CN = 2 × 2(log2 intensity). Regions of CNAs were
detected by a genomic segmentation algorithm to characterize isolated
islands of significantly higher- or lower-intensity ratios into CNA re-
gions [27]. Delineating CNA and its boundaries can often be chal-
lenging [28]. To reduce the detection of false-positive alterations
owing to inherent microarray “noise” and to achieve a balance be-
tween sensitivity and specificity, we used the following parameters:
a minimum of 10 markers (defining the smallest detectable region),
a P threshold of .0001 (controlling for outlying probes), a signal-to-
noise ratio of 0.6 [27], and an expected range of ±0.5 (distance from
normal CN). Accordingly, regions with a CN score greater than 2.5 or
less than 1.5 were considered as gains or losses, respectively. A false
discovery rate–based adjustment was always applied and performed
using the step up method with an alpha value of 0.05 [29]. CNAs
detected by genomic segmentation were visually verified using the
Partek Genome Browser. Figure W1 gives an example how the
genomic segmentation algorithm is able to specifically detect regions
of gains and losses.
Genotype analysis was performed using the Birdseed v2 algorithm
provided by the Affymetrix GTC (version 4.0), according to the rec-
ommended guidelines. The SNP call rate after genotype analysis was
greater than 95% in all samples. For the LOH analysis, CHP files
were imported into the Partek GS and the hidden Markov model
algorithm was applied. The SNP calls made by the software were
AB (heterozygous SNP), AA and BB (homozygous SNP), and no
call (if the software was unable to decide on the calls). LOH was
assumed when the normal tissue biallelic marker (AB) was found to
be monoallelic in tumor tissue. The heterozygosity rate was calculated
as the number of AB calls/total number of calls, where low hetero-
zygosity rate implies LOH (frequency of heterozygous calls for a
normal region = 0.3). The LOH data were merged with CNAs to
obtain the cnLOH. In fact, LOH events can be accompanied by allele
gains (AAA or BBB) or losses (A0 or B0) or can be defined as cnLOH
when they are not associated with CNAs (AA or BB).
The Partek workflow and the Hg19 (reference file) were used for the
gene annotation (RefSeq). The observed CNAs were checked against
the database of genomic variants (dBVar). Gene ontology enrichment
and gene family analysis of gene sets was performed using the gene set
enrichment analysis (GSEA) annotation tool. The relevance of altered
genes to currently known canonical pathways was investigated using the
MetaCore Analytical suite (Pathways Maps; GeneGo, Inc, Thomson
Reuters, St Joseph, MI). In particular, MetaCore was used to calculate
the statistical significance (P value) of the probability of assembly from a
random set of nodes (genes) of the same size as the input list (single
experiment analysis). P < .02 indicates a statistically significant non-
random association. The same software was used to characterize the
gene networks.
To quantify the known and predicted protein-protein interaction
properties, we used the search tool for the retrieval of interacting
genes/proteins (STRING, Version 9.0) database of direct (physical)
and indirect (functional) interactions [30]. The interactions are
derived from genomic content, high-throughput experiments, co-
expression, and previous knowledge [31]. A high confidence score
of 0.700 was chosen.
Correlation to Clinical Data
The comparison of clinical parameters, such as age at diagnosis,
tumor size, and hormonal secretion pattern, between groups with
or without genetic alterations was performed by appropriate statistical
methods. The Fisher exact test or the χ2 test was used to investigate
the relationship between dichotomic variables, whereas a one-way
analysis of variance model or a two-sided t test was used to test con-
tinuous variables. Correlations between different parameters were
evaluated by linear regression analysis. Statistical analyses were made
using GraphPad Prism (version 4.0; La Jolla, CA) and SPSS Software
(PASWVersion 19.0; SPSS, Inc, Chicago, IL). P < .05 was considered
statistically significant.
FISH Analysis
Selected CNAs identified by SNP array results were validated on
13 available paraffin-embedded tumor tissue samples using FISH
analysis according to previously published methods [32]. Specifically,
we investigated two chromosomal regions, one with a gain and one
with a loss according to the SNP analysis (11p15.5 and 6q23.2, respec-
tively). BAC clones (Children’s Hospital Oakland Research Institute)
were used and hybridized together with the corresponding centromere-
specific reference probe (Vysis; Abbott Molecular, Abbott Park, IL).
The probes chosen for the gained region 11p15.5 were specific for
the IGF2 locus (RP11-373H8, RP11-72D6) and those chosen for the
lost region 6q23.2 were specific for the serum glucocorticoid kinase 1
(SGK1) locus (RP11-325G4, RP11-692B5, RP11-466N7). A total
of 100 interphase nuclei were analyzed with Zeiss Axioskop 2 Micro-
scope (Carl Zeiss MicroImaging) by two independent operators, and
a ratio of red signals to green signals was calculated. The cutoff for
defining gains or losses was more than 40% cells.
Quantitative Real-time Polymerase Chain Reaction
CN validation. Quantitative real-time polymerase chain reaction
(qRT-PCR) analysis was performed on DNA samples to validate the
CN status of selected genes that were found to be altered using SNP
arrays. The corresponding blood samples were used as calibrators.
Primers for the genes IGF2, EPHA7, CYP11B2, CTNNB1, and
SGK1 were designed using the Ensembl database and the primer
BLAST tool (NCBi; TableW1). The SYBRGreen kit (qPCR Supermix;
Invitrogen, Karlsruhe, Germany), the C1000 Thermal Cycler (CFX96
real-time system; Biorad, Hercules, CA), and the Bio-Rad CFXManager
(Version 2.0) were used. Twenty nanograms of DNA was used in each
qRT-PCR, and all samples were run in duplicates. The conditions for
amplifications were 95°C for 3 minutes followed by 40 cycles of 95°C
for 15 seconds, 62°C for 15 seconds, and 72°C for 15 seconds, followed
by melting temperature curve analysis. CNAs were assessed by relative
quantification methods, using GAPDH as endogenous reference, and
were calculated as follows: 2 × 2[(Dt − DGAPDH) − (N t − NGAPDH)], where
Dt is the mean threshold cycle number for experimental primer in
tumor DNA,DGAPDH is the mean threshold cycle number forGAPDH
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primer in tumor DNA, N t is the mean threshold cycle number in ref-
erence DNA, and NGAPDH is the mean threshold cycle number for
GAPDH in reference DNA (modified from Le Bron et al. [33]).
Messenger RNA expression. Messenger RNA (mRNA) expression
of selected candidate genes was also investigated by qRT-PCR, although
the correlation between CNAs and mRNA expression is frequently
affected by several confounding factors, including epigenetic alterations,
such as methylation and miRNA expression [34], and large interindi-
vidual variation due to complex gene-gene regulation events [35]. RNA
was isolated from frozen tissue samples using the RNeasy Lipid Tissue
Minikit (Qiagen) and was reverse transcribed using the QuantiTect
Reverse Transcription Kit (Qiagen). Predesigned TaqMan gene ex-
pression assays were purchased from Applied Biosystems (Darmstadt,
Germany). Specific probes are given in the Table W1. Endogenously
expressed β-actin was used as an internal control. Forty nanograms of
cDNA was used for each PCR, and each sample was performed in
duplicate. Transcript levels were determined by using the TaqMan Gene
Expression Master Mix (Applied Biosystems), the C1000 Thermal
Cycler (CFX96 real-time system; Biorad), and the Bio-Rad CFX
Manager 2.0 software. Cycling conditions were 95°C for 3 minutes
followed by 50 cycles of 95°C for 30 seconds, 60°C for 30 seconds,
and 72°C for 30 seconds. Because of the small number of available
matched normal adrenal tissues (area surrounding the adenomas), we
could not design a threshold for altered expression based on the ratio
between tumor and matched surrounding tissues. Using the ΔCT
method [36], the gene expression levels were normalized to those of
the endogenous control β-actin, which was detected in all samples.
Results
Clinical Data
Our final study cohort included 15 tumor tissues and 15 matched
blood samples from patients with cortisol-secreting ACA (10 women
and 5 men; mean age at diagnosis, 47.5 ± 12.3 years). Eight patients
had subclinical and seven had overt hypercortisolism. The mean diam-
eter of the tumors was 4.2 ± 2.0 cm. Detailed clinical, pathologic, and
corresponding genetic characteristics are provided in Table 1.
SNP Array Profiling Allowed the Identification of Recurrent
CN Alterations in ACA
CN profiling revealed a total of 962 CNAs (564 gains and 398 losses).
All cases were affected by at least two aberration with a median of
18 CNAs per sample (range, 2-284) showing a highly variable pattern
(Table 1 and Figure 1). The chromosomes with the most frequent gains
were chr 5, 3, 6, 11, and 2, whereas chromosomes with most frequent
losses were chr 1, 6, and 2. The median length of CNAs was 29,071 bp
(range, 587-7.71e7 bp). Large alterations (>100 kb) were rare events
(11% of total), although they were found in most cases (12/15 adenomas;
median per sample, 3; range, 0-82). CNAs longer than 10 Mb were
observed in only 4/15 samples, involving the chromosomal regions
1p36.12-31.3 (loss), 1q21.1-23.1 and 1q24.2-31.2 (gain), 6q23.3-
25.3 (loss) and 9q34.11-ter (gain), 17q11.2-25.3 (loss), 18p11.32-ter
(loss), and 19p13.2-p12 (gain).
The list of all detected CNAs, including cytobands, type of alter-
ation, length, number of markers, CN score, and overlapping genes
according to the RefSeq database is provided in Table W2.
Several alterations were detected in intergenic regions, often localized
at centromeric or telomeric segments (∼50% of total CNAs). Thus,
only 471 CNAs (198 gains and 273 losses; median per sample, 11;
range, 0-197) were localized in regions with known genes.
Only 28% of all detected alterations were observed in at least two
cases (i.e., minimal overlapping regions), indicating a high genetic
variability among the samples. Considering only the aberrations
found in regions coding for known genes, we observed 89 recurrent
CNAs (51 gains and 38 losses) involving 73 chromosomal regions
and 753 overlapping genes (Table W3). Among these, 18 gains had
a CN score higher than 4.0, consistent with an amplification, and
three losses had a CN score less than 1.0, which might be consistent
with a homozygous deletion. However, no losses with a CN score
less than 0.5 were observed that would clearly indicate a homo-
zygous deletion.
In particular, 13 gains were recurrent in at least three cases (maximal
frequency, ≥20%; median length, 1.85 Mb; Table W3). These altera-
tions involved 11 chromosomal regions, 5 of them being in line with
previous publication (Table 2). Intriguingly, most of them, namely gains
in 5p15.33, 7p22.3-22.2, 8q24.3, 9q34.2-34.3, 11p15.5, 16q24.3, and
Xq28, affected the same three ACAs (nos. 802A, 271A, and 207A)
Table 1. Summary of Clinical Features and Genetic Alterations Observed by the SNP Microarray Analysis (CNAs and cnLOH) of 15 Patients with Cortisol-Secreting ACA.
Patients Sex/Age Tumor Size (cm) Hormonal Pattern* Time of Follow-up (mo) No. CNA (Gain/Loss) No. cnLOH
1 (350A) F/35 1.5 Subclinical 47 284 (30/254) 0
2 (802A) F/55 6.5 Overt 29 237 (229/8) 0
3 (283A) F/43 2.8 Subclinical 61 148 (148/0) 2
4 (312A) M/71 11.0 Overt 60 123 (24/99) 1
5 (474A) F/42 1.8 Overt 39 46 (46/0) 0
6 (170A) M/53 5.0 Subclinical 151 34 (34/0) 3
7 (178A) M/65 6.0 Subclinical 115 20 (4/16) 0
8 (207A) F/41 3.0 Overt 99 18 (16/2) 0
9 (271A) F/43 3.0 Overt 66 18 (13/5) 0
10 (967A) F/29 3.3 Overt 14 13 (8/5) 0
11 (923A) M/55 4.0 Subclinical 20 9 (6/3) 14
12 (223A) F/45 NK Overt 120 4 (1/3) 0
13 (1013A) F/29 2.0 Subclinical 7 3 (2/1) 0
14 (226A) M/47 2.5 Subclinical 82 3 (1/2) 0
15 (317A) F/60 4.3 Subclinical 92 2 (2/0) 0
Mean 47.5 4.0 66.8 64.1 1.4
SD 12.3 2.5 42.6 91.3 3.7
Median 45.0 3.2 61.0 18 (13/3) 0
NK indicates not known.
*Overt or subclinical hypercortisolism according to previously described criteria [21].
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associated with overt Cushing syndrome. Notably, potential candidate
genes such as NOTCH1, HRAS, IGF2, CYP2W1, and CYP11B2 are
mapped in these regions.
The presence of the gain at 11p15.5 (IGF2 locus) was also con-
firmed by FISH analysis in two of the three cases observed by SNP
array (nos. 207A and 271A; data not shown).
Conversely, losses were all less than 1 Mb and occurred at most
in two different samples. They were mostly localized in chr 1
(at 1p36.12-1p36.11, 1p34.2, 1p33, and 1q23.1), in chr 2 (at
2p16.2-16.1 and 2q11.2), at 3p22.1, at 6q21-26, in chr 11q (at
11q23.2 and 11q24.1-24.2), and in chr 18 (at 18p11.2-11.31 and
18q12.2) (Table W3).
Figure 1. Genome-wide distribution of DNA CNAs in each cortisol-secreting adrenocortical benign tumor (n = 15). CN gains are repre-
sented in red and CN losses in blue.
Table 2. Chromosomal Regions with Most Frequent Gains (Minimal Overlapping Regions) Coding for Known Genes Observed in at Least 3/15 Cortisol-Secreting ACAs (Frequency, ≥20%) According
to CNAs Detected by SNP Arrays.
Cytoband Altered Samples No. Genes Selected Genes
Already reported regions*
5p15.33 207A, 271A, 802A 28 NKD2, PDCD6
9q34.2-34.3 207A, 271A, 802A 100 COBRA1, EDF1, FBXW5, LHX3, NOTCH1, RXRA, SNAPC4, TRAF2
12q12 1
16q24.3- 207A, 271A, 802A 14 FANCA, MC1R, PRDM7
20p11.1-q11.21 170A, 283A, 802A 3
Newly observed regions
6q16.1 283A, 474A, 802A 1 EPHA7
7p22.3-22.2 207A, 271A, 802A 34 CYP2W1, MAFK, NUDT1, PDGFA, PRKAR1B, UNCX
8q24.3 207A, 271A, 802A 102 ARC, BAI1, SLURP1, ADCK5, CYP11B2, FOXH1, HSF1, LRRC14, MAFA, MAPK15, MFSD3, PUF60, RECQL4
11p15.5 207A, 271A, 802A 74 CD151, CTSD, H19, HRAS, IFITM1, IGF2, INS, INS-IGF2, IRF7, LRDD, PHRF1, RPLP2, SCT
11q11 283A, 350A, 802A 3
Xq28 207A, 271A, 802A 81 DKC1, IRAK1, L1CAM, MECP2
Selected genes: genes considered relevant for tumorigenesis or glucocorticoid production/effects. They include potential oncogenes and tumor suppressor genes, growth or transcription factors, cell
differentiation markers, protein kinases (according to the gene set enrichment analysis, see also Table W4), genes involved in steroidogenesis (underlined), or glucocorticoid regulation or in Wnt/β-
catenin signaling.
Localization, length, and CN score of the CNAs are reported in Table W3.
*Regions already reported in previous studies with conventional comparative genomic hybridization [3,12,13].
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ACA Are Affected by Recurrent Microalterations
The extremely high-resolution allowed us to identify 309 CN
microalterations (127 gains and 182 losses, 66% of CNAs in regions
coding for known genes) that involved 285 single genes (including
60 introns). Some of these microalterations affected only specific
structural regions of single genes.
Forty-six of these small alterations occurred in two or more cases
(18 gains, 13 amplifications, and 15 losses; Table 3). A representative
example of recurrent microamplification at the ephrin receptor 7
(EPHA7 ) gene is shown in Figure 2. With the exception of a gain
in 10p11.21, none of these microalterations have been reported pre-
viously in human tissue samples from healthy subjects (according to
the dBVar).
The presence of the microdeletion at 6q23.2 (locus for SGK1) in
sample 350 was confirmed also by FISH analysis showing a locus-
specific loss for SGK1 in more than 80% of the cells (Figure 3). Be-
cause no paraffin block from the other tumor affected by a loss of
SGK1 locus (no. 312A) was available, no confirmation by FISH
was possible.
ACA Are Affected by cnLOH
We identified 23 LOH events in 12 regions on chr 1, 7, 9, 11,
and 16, involving 5/15 adenomas. The median length of these altera-
tions was 69,420 bp (range, 1,526-4,495,281 bp). None of the re-
gions with LOH were also affected by a CN loss, suggesting that all
the LOH occurred along with a gain of the remaining chromosomal
copy. Specifically, three LOHs were associated with a gain (at 1q23.3
and 9q31.2), whereas 20 were cnLOH events (Table 4). cnLOH
events were observed in 4 different adenomas (26.6%) and distributed
on 11 chromosomal regions with a median size of 108,415 bp (range,
25,701-3,445,898 bp), 16q being the most frequently altered regions.
Overall, 15 known genes were affected, including the potential tumor
Table 3. Most Frequent Microalterations Involving Single Genes in 15 Cortisol-Secreting ACAs According to CNAs Detected by High-resolution SNP Arrays.
Cytoband n (%) CNA CN Score Gene Description
12q12 3 (20) Gain 5.23 Contained within C12orf40 Chromosome 12 open reading frame 40
6q16.1 3 (20) Gain 4.33 Contained within EPHA7 Ephrin receptor 7
9q34.3 3 (20) Gain 3.64 Overlap with 51% of FAM157B Family with sequence similarity 157, member B
2q11.2 2 (13) Gain 4.71 Intron of C2orf55 Chromosome 2 open reading frame 55
Xq22.3 2 (13) Gain 4.60 Contained within IL1RAPL2 Interleukin 1 receptor accessory protein-like 2
11q14.1 2 (13) Gain 4.57 Intron of DLG2 Discs large homolog 2
12q21.31 2 (13) Gain 4.51 Intron of MGAT4C Mannosyl-glycoprotein β-1,4-N -acetylglucosaminyltransferase, isozyme C
2q24.3 2 (13) Gain 4.36 Contained within SCN9A Sodium channel, voltage-gated, type IX, α subunit
12q21.32 2 (13) Gain 4.27 Intron of KITLG KIT ligand
14q21.3 2 (13) Gain 4.26 Contained within MDGA2 MAM domain containing glycosylphosphatidylinositol anchor 2
12q13.3 2 (13) Gain 4.02 TAC3 Tachykinin 3
4p15.31 2 (13) Gain 4.00 Intron of KCNIP4 Kv channel interacting protein 4
3p14.2 2 (13) Gain 3.95 Intron of FHIT Fragile histidine triad gene
10q11.21 2 (13) Gain 3.92 Overlap with 54% of ZNF33B Zinc finger protein 33B
10p11.21 2 (13) Gain 3.91 Contained within ANKRD30A Ankyrin repeat domain 30A
2p12 2 (13) Gain 3.85 Intron of LRRTM4 Leucine-rich repeat transmembrane neuronal 4
10q21.1 2 (13) Gain 3.81 Intron of PRKG1 Protein kinase, cGMP-dependent, type I
13q14.2 2 (13) Gain 3.79 Intron of CAB39L Calcium binding protein 39-like
1q44 2 (13) Gain 3.68 Intron of KIF26B Kinesin family member 26B
18q12.3 2 (13) Gain 3.49 Intron of RIT2 Ras-like without CAAX 2
11p11.12 2 (13) Gain 3.34 OR4A5 Olfactory receptor family 4 subfamily A member 5
7p13 2 (13) Gain 3.10 Contained within CAMK2B Calcium/calmodulin-dependent protein kinase II β
Xq28 2 (13) Gain 2.91 Overlap with 88% of IDH3G Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial precursor
Xq28 2 (13) Gain 2.83 Intron of F8 Coagulation factor VIII precursor
7p22.2 2 (13) Gain 2.73 Intron of GNA12 G protein alpha 12
8q24.3 2 (13) Gain 2.64 CYP11B1 Cytochrome P450 11B1, mitochondrial precursor
8q24.3 2 (13) Gain 2.64 C8orf33 Chromosome 8 open reading frame 33
5p15.33 2 (13) Gain 2.61 IRX4 Iroquois homeobox 4
6q23.2 2 (13) Loss 0.84 Contained within SGK1 Serum/glucocorticoid-regulated kinase 1
2q11.2 2 (13) Loss 0.88 Intron of NPAS2 Neuronal PAS domain protein 2
3p22.1 2 (13) Loss 0.96 Contained within CTNNB1 Catenin (cadherin-associated protein), β 1
6q22.31 2 (13) Loss 1.00 HEY2 Hairy/enhancer-of-split related with YRPW motif 2
6q26 2 (13) Loss 1.01 Contained within QKI Quackin protein
18q11.2 2 (13) Loss 1.10 Contained within LAMA3 Laminin subunit alpha-3 precursor
6q21 2 (13) Loss 1.02 Overlap with 70% of REV3L DNA polymerase zeta catalytic subunit
2p16.2-.1 2 (13) Loss 1.03 Overlap with 50% of EML6 Echinoderm microtubule-associated protein like 6
1q23.1 2 (13) Loss 1.12 CD5L CD5 antigen-like precursor
6q23.3 2 (13) Loss 1.13 Contained within KIAA1244
1p36.11 2 (13) Loss 1.16 Overlap with 60% of TMEM57 Macoilin (transmembrane protein 57)
11q23.2 2 (13) Loss 1.16 FAM55D Family with sequence similarity 55, member D
18q12.2 2 (13) Loss 1.18 Intron of FHOD3 FH1/FH2 domain-containing protein 3
6q23.1 2 (13) Loss 1.29 Contained within EPB41L2 Erythrocyte membrane band 4.1-like protein 2
6q25.2 2 (13) Loss 1.31 Overlap with 81% of RGS17 Regulator of G protein signaling 17
1p33 2 (13) Loss 1.34 STIL SCL-interrupting locus protein
6q26 2 (13) Loss 1.35 Intron of PACRG PARK2 coregulated
6q25.1-.2 2 (13) Loss 1.36 Overlap with 80% of SYNE1 Synaptic nuclear envelope protein 1
Only CNAs involving one entire gene or contained within one gene or overlapping with more than 50% of one gene are reported.
Genes in bold: genes considered relevant for tumorigenesis or glucocorticoid production/effects. They include potential oncogenes and tumor suppressor genes, growth or transcription factors, cell
differentiation markers, protein kinases (according to GSEA; see also Table W4), genes involved in steroidogenesis (underlined) or glucocorticoid regulation or in Wnt/β-catenin signaling.
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Figure 2. A representative example of a single gene (ephrin receptor 7 [EPHA7] at chr 6q16.1; entire length, 179,563 bp) affected by a
recurrent SNP-detected microamplification. The heat map shows the intensity plots in each sample (defined with sample ID). Gains/
amplifications are represented in red and losses/deletions in blue. The CN profile is shown for three altered cases (nos. 283A, 474A,
802A). The genomic browser wizard shows the altered regions (gains represented in red and losses in blue) according to the genomic
segmentation (Partek GS). Minimal overlapping regions in at least 2 samples (MORs) are reported in the upper panel (length of the MOR,
14,544 bp).
Figure 3. Validation with FISH analysis of the CNAs detected with SNP array. Representative FISH-validated case with CN loss at the
SGK1 locus (probe at 6q23.2) according to the SNP analysis (sample no. 350A): loss of the red signal (specific for the SGK1 probe) with
respect to the green signal (centromere-specific reference probe) in more than 80% of cells. Arrows indicate the additional green signals,
whereas red circles underline the red signals.
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suppressor gene bromodomain containing 7 (BRD7) mapped at 16q12.1
(Table 4).
Correlation between CNA and Clinical Features
Tumor size positively correlated with the number of large CNAs
(>100 kb, P = .042, r = 0.28). This was even more evident when only
large losses were considered (P = .039, r = 0.56). Cortisol levels after
DST correlated with the number of large gains. However, this cor-
relation was not significant. In addition, all the three adenomas that
were affected by the most common large CN gains (nos. 802A,
207A, and 271A) had an overt hypercortisolism.
No significant correlations between the total number of detected
CNAs and/or cnLOH and the clinical parameters, such as sex, age at
diagnosis, tumor size, hormonal hypersecretion, body mass index,
blood pressure, and duration of follow-up, were found in our series.
Moreover, no differences were observed between different subgroups
of patients regarding tumor size or severity of hypercortisolism.
Identification of Candidate Genes
We analyzed all the 753 genes with CN gains or losses in at least
two cases (listed in Table W3) and 638 known overlapping genes
were recognized in Gene Ontology (572 gained and 66 lost). Inter-
estingly, among the genes with CN gains, 19 microRNAs (including
MIR483, MIR126, and MIR675), three small nucleolar RNA and
two noncoding RNA have also been recognized (Table W3).
Using the GSEA tool, the annotation to gene families showed sev-
eral transcription factors (n = 48) and protein kinases (n = 15), espe-
cially among the genes with CN gains (Table W4).
The MetaCore analysis was also applied on these 753 genes to
examine their association with known canonical pathways (GeneGO
Pathways Maps). The most significant recognized pathway was the
Notch signaling (P = 1.494e−6). It was followed by the Wnt and
Notch signaling in early cardiac myogenesis (P = 4.287e−6) and in
osteogenesis (P = 1.094e−5), by the reverse signaling by Ephrin B,
which also includes the Wnt/β-catenin pathway (P = 2.549e−5) and
the WNT5A signaling pathway (P = 2.764e−5). The first two most
significant pathways and their associated genes are shown in the
Figure W2, A and B, whereas the entire Notch signaling gene net-
work and its known connections with the Wnt/β-catenin signaling
pathway is shown in Figure W3 (GeneGO).
According to the global STRING-generated protein-protein
network including the same group of genes, we observed that
CTNNB1 and INS/IGF2 were among the most central molecules
(data not shown).
Among the 285 annotated genes affected by chromosomal micro-
amplifications, we recognized protein kinases (such as CAMK2B,
EPHA7, PRKG1), the growth factor KITLG, the tumor suppressor
gene FHIT, the suggested transforming oncogene GNA12, the steroid
11-β-hydroxylase CYP11B1, and ion channels (such as SCN9A and
KCNIP4), as particular interesting; whereas among genes affected by
microdeletions, we recognized transcription factors, such as HEY2,
NPAS2, and REV3L, the protein kinase SGK1, and the oncogenes
CTNNB1 and STIL (Tables 3, W3, and W4).
By STRING analysis including only genes with microalterations
recurrent in at least two samples (n = 46), the most central interactions
were observed between CTNNB1 and FHIT, SGK1, and KITLG
(Figure W4).
The validation with qRT-PCR at the DNA level for single altered
genes showed a reasonable fit for SGK1 (75% correspondence),
CTNNB1 and EPHA7 (64% correspondence). Most discrepancies to
SNP arrays results were observed in alterations with CN scores close
to the cutoff level (Figure 4A).
mRNA Expression of Candidate Genes
The mRNA expression levels of selected candidate genes from
amplified (IGF2, EPHA7, CYP11B1, CYP11B2, NOTCH1, HRAS,
and FHIT ) and deleted areas (SGK1 and CTNNB1) were analyzed
by qRT-PCR. Owing to the small number of detected CNA, a sta-
tistical comparison between SNP results and gene expression was not
feasible. However, interestingly, the chromosomal gains within the
CYP11B1 locus and the losses within the SGK1 locus showed an
association with an increase and a decrease in mRNA expression levels,
respectively (Figure 4B).
Discussion
We here provide for the first time a genome-wide and high-resolution
view of chromosomal changes in benign adrenocortical tumors, based
on SNP arrays 6.0 covering simultaneously CNA and LOH. Previous
studies have established SNP arrays as a powerful tool to detect DNA
changes in solid tumors, revealing loci and candidate genes possibly
involved in tumorigenesis [22–24]. To reduce the influence of disease
Table 4. LOH Events Detected by High-resolution SNP Arrays in 15 Cortisol-Secreting ACAs.
Cytoband No. LOH Type of Alteration Length (bp) Altered Sample HR Overlapping Genes
1p33 1 cnLOH 25,701 312A 0.17 Region overlaps with 90% of CMPK1
1q23.3 2 LOH + gain 61,241 312A 0 Intron of PBX1
7q11.21 2 cnLOH 108,415 283A 0 LOC643955
9q31.2 1 LOH + gain 6,944 802A 0 Not coding
11p11.12-11q11 2 cnLOH 3,445,898 170A 0.012 OR4C46
11q11 1 cnLOH 74,179 170A 0.012 TRIM48
16q12.1 1 cnLOH 215,106 923A 0.14 ADCY7, BRD7
12.2 3 58,676 0.077 Intron of FTO, region overlaps
with 70% of RPGRIP1L
16q21-22.1 4 cnLOH 111,178 923A 0.018 CKLF, CMTM1, CMTM2, TK2
16q23.1 3 cnLOH 336,158 923A 0.021 Region overlaps with 62% of CNTNAP4,
region overlaps with 60% of VAT1
23.2 1 47,149 0.067 Not coding
16q24.1 1 cnLOH 11,758 923A 0 Not coding
24.2 1 25,499 0.095 Region overlaps with 83% of ZCCHC14
BRD7 indicates potential tumor suppressor gene; HR, heterozygous rate.
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heterogeneity and false-positives, we focused on cortisol-secreting
ACAs using a paired analysis approach with corresponding blood
samples and a stringent mathematical algorithm. This method allowed
us to identify novel chromosomal regions affected by CNA and novel
promising candidate genes. Moreover, we were able to recognize among
the altered genes, several members of signaling pathways that, until
now, have not been associated with adrenocortical tumorigenesis.
CNAs were invariably observed in all our cases with a rather high
median number of CNAs per sample. In contrast, previous cytogenetic
studies applying CGH on benign adrenocortical tumors had revealed
only few gains or losses [14–16,18,19]. This discrepancy reflects the
much higher resolution of the Affymetrix SNP 6.0 array platform
(estimated resolution limit of 7 kb) compared with CGH (10 Mb
for conventional CGH and of 150 kb for array CGH). Accordingly,
most of the detected CNAs were microalterations (89% of total). How-
ever, consistent with previous findings [14,16–18], we found a high
variability of the number of CNAs among different samples and a
significant correlation with the tumor size when considering only the
longer alterations (>100 kb).
Recurrent CN Gains and Candidate Genes
We observed frequent CN gains (≥20% of cases) in already reported
regions, confirming the reliability of our SNP array analysis but also in
not-yet-described regions (Table 2). In all these regions, we identified
Figure 4. (A) Validation of CNAs detected with SNP array. CNA analysis by qRT-PCR at the DNA level for five selected candidate genes
with gains (CYP11B2, EPHA7, IGF2) or losses (CTNNB1, SGK1) according to the SNP array analysis. CN score of 2 corresponds to normal CN;
CN score greater than 2.5, CN gain; CN score less than 1.5, CN loss. The best fit was observed for the genes SGK1 (75% correspondence),
CTNNB1 and EPHA7 (64% correspondence). (B) Relative mRNA expression levels evaluated by qRT-PCR for two selected candidate genes
(CYP11B1 and SGK1) according to the CN status observed with SNP array analysis. The gene actin beta was used as a loading control
(reference gene).
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candidate genes, which have not been implicated in adrenal tumori-
genesis so far. In particular, we were able to confirm gains at chr 5,
9q (telomeric region), 12q, and chr 16 [14–16,18], and interestingly,
we could narrow down these regions to smaller segments such as
5p15.33, 9q34.2-34.3, 12q12, and 16q24.3-tel.
Notably, we did not recognize at 9q34 alterations in the NR5A1
gene coding for the steroidogenic factor (SF-1), which is involved in
the regulation of steroid biosynthesis and is a marker to differentiate
between tumors of adrenocortical and nonadrenocortical origin [37].
Similar results have been obtained with SNP array profiling in child-
hood adrenocortical tumors (E. Lalli, personal communication), maybe
suggesting that other mechanisms may account to SF1 overexpression
and/or that other genes in this region may play an important pathoge-
netic role. In fact, the 9q34 region comprised among others the
NOTCH1 gene, which plays a role in a variety of developmental pro-
cesses and tumorigenesis by controlling cell fate decisions. In particular,
Notch1 may either suppress or promote tumor development and pro-
gression depending on cell type and context [38]. For instance, Notch1
is inactive in several neuroendocrine malignancies, including medullary
thyroid cancer, carcinoid, and small cell lung cancer.
Among the newly observed regions with gains, the 11p15.5 im-
printed locus, which comprises several genes like IGF2, INS, INS-
IGF2, and H19, is of particular interest. It is well known that in
ACC paternal isodisomy in this locus (cnLOH) leads to IGF2 over-
expression, which is correlated with malignancy [39]. On the basis of
our findings, it could be hypothesized that a gain of the paternal
allele in this region acts as a “first hit” in the development of ACC.
The loss of the maternal allele might then act as a “second hit”
(cnLOH), leading to IGF2 overexpression and malignant progression.
Thus, these observations could be a hint toward a stepwise progression
from a benign to a malignant phenotype in adrenal tumorigenesis.
Moreover, the well-known oncogene HRAS, which was previously
found to be occasionally mutated in ACC [40] and which might play
a supporting role in tumor progression, is also included among gained
genes at 11p15.5.
Notably, among the altered genes mapped in many of the recur-
rently gained regions (i.e., at 7p22.3-22.2, 8q24.3, 9q34.2-34.3,
11p15.5, 1p36.3-36.2, 10q26.3, and 16p13.3), we recognized sev-
eral microRNAs that could theoretically regulate gene expression. In
particular, they included the MIR483 and MIR675, which have
already been reported to be altered in adrenocortical tumors [41,42].
Even more interestingly, most of the recurrent gains were identi-
fied in the same three ACAs that all had an overt hypercortisolism
(20% of all patients, 43% of patients with overt hypercortisolism).
Specifically, they were localized in seven different chromosomes
(namely at 5p15.33, 7p22.3-22.2, 8q24.3, 9q34.2-34.3, 11p15.5,
16q24.3, and Xq28). It could be hypothesized that these recurrent
alterations could affect early adrenocortical tumorigenesis and/or on
corticosteroid overproduction. Accordingly, several pathophysiologi-
cally relevant genes, including the known oncogenes NOTCH1 and
HRAS, the IGF2, involved in adrenocortical tumor development,
and the aldosterone-synthase CYP11B2 were located in these regions.
Moreover, two of these three ACAs had also an additional micro-
amplification in the gene coding for the 11-β-hydroxylase (CYP11B1),
which was also somehow correlated with a high mRNA expression.
Nevertheless, the gains found at CYP11B2 were not associated with
both mRNA expression and clinical data. These findings further sug-
gest a possible role of CN gains in genes coding for enzymes involved in
steroidogenesis on hormonal hypersecretion pathogenesis.
Recurrent Microalterations and Candidate Genes
One of the most striking finding was the observation that many
CNAs affected only single genes (Table 3), which represent a major
advantage of this study compared with previous investigations using
CGH. The most frequent microamplification (n = 3) was detected in
the gene EPHA7, which was confirmed in two cases by DNA qRT-
PCR. The ephrin receptors represent the largest family of receptor
tyrosine kinases. They are frequently overexpressed in a wide variety
of cancer types, but they can be downregulated in advanced tumor
stages [43], thus representing potential promising therapeutic targets
in cancer. We observed gains contained in EPHA7 in three adenomas,
and additional single cases had gains in EPHA6, EPHB3 or EPHB4
or losses in EPHA6, EPHA8, or EPHB2, suggesting a role of the
ephrin receptor family in adrenocortical tumorigenesis, which needs
further investigation.
We also observed, among others, microdeletions in the genesCTNNB1
and SGK1 (frequency,≥13%), whose central role among other associa-
tions was supported by the STRING analysis. Constitutive activating
mutations in CTNNB1 are known to be frequent in adrenocortical
tumors, usually leading to a β-catenin accumulation in the cytoplasm
and translocation to the nucleus, and are found to correlate with poor
prognosis in ACC and hormonal inactivity [11]. Nevertheless, somatic
CTNNB1 mutations may explain only approximately 50% of the β-
catenin accumulation, indicating that other components of the Wnt
pathway may be involved [44]. No data about CNAs or other genetic
changes in CTNNB1 existed so far, and the effective role of a CN loss
in benign tumors remains to be better characterized.
SGK1 is a ubiquitously expressed serine/threonine kinase originally
cloned as a glucocorticoid early-response gene. Its expression is up-
regulated by a number of other factors including β-catenin [11,45]
and is activated by p53 [46]. SGK1 is a downstream effector of
phosphatidylinositide-3-kinase and is involved in several biologic
functions, including cell survival, and may be involved in resistance
to chemotherapy [47]. However, its definitive role on tumor growth is
still conflicting, as its expression is upregulated in some tumors and
downregulated in others. SGK1 expression and function have been
recently investigated in corticotroph cell lines [48], in response to
corticosterone elevation induced by stress in mice [49] and in several
cancers [50], but its role in adrenocortical tumors and/or endogenous
hypecortisolism is unknown. CN losses in SGK1 gene were also con-
firmed by FISH and DNA qRT-PCR analysis and corresponded to a
low mRNA expression level.
cnLOH and Candidate Genes
Another relevant advantage of SNP arrays is the possibility to also
detect cnLOH (or UPD). Accordingly, the number of UPD cases
reported in the literature has recently increased exponentially and re-
current cnLOHs have been reported in many cancer types, possibly
constituting an important driving force in cancer [51]. In fact, it has
been shown that neoplastic cells not only depend on structural altera-
tions of genetic material but also on the presence of cnLOH, which
may produce homozygosity for a preexisting tumor somatic muta-
tion [27]. In our series, we detected only a few small cnLOH, none
of them being observed in more than one sample, likely because of
the benign nature of our tumors. However, some interesting genes
were mapped into regions of cnLOH, such as BRD7, a potential
tumor suppressor gene acting as a transcriptional cofactor for p53.
The potential pathogenetic role of these alterations remains to
be elucidated.
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Candidate Signaling Pathways
According to a pathway analysis including the 753 genes altered in
at least two cases, the Notch1 and the Wnt/β-catenin signaling were
the most significantly affected pathways. In fact, we observed CN gains
or losses in several genes involved in different steps of the Notch1 (i.e.,
namely p73, NOTCH1, HES4, HES5, HEY2, CTNNB1) and/or the
Wnt/β-catenin pathway (i.e., LRP5,DVL1, AXIN1,NKD2, CTNNB1,
SGK1), which are closely interconnected. On one hand, a constitutive
activation of the Wnt/β-catenin signaling pathway is well known to be
common in adrenocortical tumors, but the underlyingmolecular mech-
anism is only partially elucidated [11–13]. Nevertheless, an aberrant
Notch signaling has been linked to a wide variety of tumors such as
small cell lung cancer, neuroblastoma, cervical, and prostate cancer,
but it has not been yet implicated in adrenocortical neoplasias. In ad-
dition, it is known that the Notch1 and the Wnt/β-catenin pathways
interact in different contexts and comprise genes that regulate each
other transcriptionally [52]. For instance, activation of Notch signaling
is β-catenin dependent in melanoma progression [53], whereas an
antioncogenic effect seemed to be mediated by p21 induction and
Wnt signaling repression in skin carcinogenesis. In this context, as
shown in the Figure 5, a relevant role might be also suggested for other
factors, such as SGK1, which is also a target gene of β-catenin. In fact,
stimulation of SGK1 by glucocorticoids, in combination with activated
PKB/Akt complex, phosphorylates glycogen-synthase-kinase-3 to in-
activate this kinase, thus inhibiting β-catenin degradation in the protea-
some and producing a stabilized hypophosphorylated form of β-catenin
[54]. It has also been demonstrated that SGK1 negatively controls
Notch1 protein expression and transcriptional activity by modulating
intracellular Notch1 stability through Fbw7 phosphorylation [55]. Our
findings obtained with pathway analysis reveal a novel potential role of
Notch signaling pathway disruption and a possible key connection with
Wnt/β-catenin signaling in early adrenocortical tumorigenesis. A fur-
ther confirmation of the supposed Notch1 signaling pathway activation
(i.e., through the investigation of the specific target genes) and a more
detailed understanding of its potential molecular interactions may pro-
vide a framework for future therapies targeting these pathways and
downstream genes.
In summary, our findings provide the first high-resolution genome-
wide view of genomic changes in benign adrenocortical cortisol-secreting
tumors, revealing recurrent gains and losses in novel chromosomal
Figure 5. Graphical representation of the known connections between the Wnt/β-catenin pathway and the Notch1 signaling pathways,
according to the knowledge of the current literature. Additional factors, such as SGK1, are also reported. Sources are represented by
previous articles [11,46–49]. Genes with CNAs according to the SNP array analysis (gains or losses) in at least two samples from our
series of 15 cortisol-secreting ACAs (frequency, ≥13%) are reported in red with an asterisk. NEXT indicates Notch extracellular domain;
NICD, Notch intracellular domain.
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regions and identifying new candidate genes, such as HRAS, EPHA7,
and SGK1, which might be involved in early tumorigenesis. Further-
more, our results suggest a potential important role of the Notch1 sig-
naling and its connections with theWnt/β-catenin signaling pathway in
the molecular pathogenesis of benign cortisol-secreting tumors.
Acknowledgments
The authors thank the technical assistants for expert and kind help,
including Luitgard Kraus for DNA extraction, Sonja Steinhauer for
RNA extraction and cDNA transcription, and Theodora Nedeva for
SNP microarray and FISH analysis performance.
References
[1] Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, and Bornstein SR
(2004). The clinically inapparent adrenal mass: update in diagnosis and man-
agement. Endocr Rev 25, 309–340.
[2] Fassnacht M, Libe R, Kroiss M, and Allolio B (2011). Adrenocortical carcinoma:
a clinician’s update. Nat Rev Endocrinol 7, 323–335.
[3] Bernard MH, Sidhu S, Berger N, Peix JL, Marsh DJ, Robinson BG, Gaston V,
Le Bouc Y, and Gicquel C (2003). A case report in favor of a multistep adre-
nocortical tumorigenesis. J Clin Endocrinol Metab 88, 998–1001.
[4] Barzon L, Sonino N, Fallo F, Palu G, and Boscaro M (2003). Prevalence and
natural history of adrenal incidentalomas. Eur J Endocrinol 149, 273–285.
[5] Bassett MH, Mayhew B, Rehman K, White PC, Mantero F, Arnaldi G, Stewart
PM, Bujalska I, and Rainey WE (2005). Expression profiles for steroidogenic
enzymes in adrenocortical disease. J Clin Endocrinol Metab 90, 5446–5455.
[6] Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U,
Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, et al. (2001). Incidence
and late prognosis of Cushing’s syndrome: a population-based study. J Clin
Endocrinol Metab 86, 117–123.
[7] Ragazzon B, Assie G, and Bertherat J (2011). Transcriptome analysis of adre-
nocortical cancers: from molecular classification to the identification of new
treatments. Endocr Relat Cancer 18, R15–R27.
[8] Stratakis CA (2009). New genes and/or molecular pathways associated with
adrenal hyperplasias and related adrenocortical tumors. Mol Cell Endocrinol
300, 152–157.
[9] Sidhu S, Gicquel C, Bambach CP, Campbell P, Magarey C, Robinson BG, and
Delbridge LW (2003). Clinical and molecular aspects of adrenocortical tumour-
igenesis. ANZ J Surg 73, 727–738.
[10] Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J,
Chapuis Y, Duclos JM, Schlumberger M, et al. (2001). Molecular markers and
long-term recurrences in a large cohort of patients with sporadic adrenocortical
tumors. Cancer Res 61, 6762–6767.
[11] Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libe R,
Rene-Corail F, Audebourg A, Vacher-Lavenu MC, et al. (2011). Wnt/β-catenin
pathway activation in adrenocortical adenomas is frequently due to somatic
CTNNB1-activating mutations, which are associated with larger and nonsecreting
tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol
Metab 96, E419–E426.
[12] Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I,
Audebourg A, Royer B, Sbiera S, et al. (2011). β-Catenin activation is associated
with specific clinical and pathologic characteristics and a poor outcome in
adrenocortical carcinoma. Clin Cancer Res 17, 328–336.
[13] Tadjine M, Lampron A, Ouadi L, and Bourdeau I (2008). Frequent mutations
of β-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol
(Oxf ) 68, 264–270.
[14] Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, and Lichter P
(2000). Adrenocortical carcinoma is characterized by a high frequency of chromo-
somal gains and high-level amplifications. Genes Chromosomes Cancer 28, 145–152.
[15] Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P,
Magarey CJ, Russell CF, Schulte KM, Roher HD, et al. (2002). Comparative
genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol
Metab 87, 3467–3474.
[16] Zhao J, Speel EJ, Muletta-Feurer S, Rutimann K, Saremaslani P, Roth J, Heitz
PU, and Komminoth P (1999). Analysis of genomic alterations in sporadic
adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical
tumorigenesis. Am J Pathol 155, 1039–1045.
[17] Gruschwitz T, Breza J, Wunderlich H, and Junker K (2010). Improvement of
histopathological classification of adrenal gland tumors by genetic differentia-
tion. World J Urol 28, 329–334.
[18] KjellmanM, Kallioniemi OP, Karhu R, Hoog A, Farnebo LO, Auer G, Larsson C,
and Backdahl M (1996). Genetic aberrations in adrenocortical tumors detected
using comparative genomic hybridization correlate with tumor size and malignancy.
Cancer Res 56, 4219–4223.
[19] Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, and Komminoth P
(2002). Combined comparative genomic hybridization and genomic microarray
for detection of gene amplifications in pulmonary artery intimal sarcomas and
adrenocortical tumors. Genes Chromosomes Cancer 34, 48–57.
[20] Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM, and
Demeure MJ (2008). Adrenocortical carcinoma survival rates correlated to genomic
copy number variants. Mol Cancer Ther 7, 425–431.
[21] Szabo PM, Tamasi V, Molnar V, Andrasfalvy M, Tombol Z, Farkas R, Kovesdi K,
Patocs A, Toth M, Szalai C, et al. (2010). Meta-analysis of adrenocortical
tumour genomics data: novel pathogenic pathways revealed. Oncogene 29,
3163–3172.
[22] LaFramboise T (2009). Single nucleotide polymorphism arrays: a decade of
biological, computational and technological advances. Nucleic Acids Res 37,
4181–4193.
[23] Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, Grigorova M,
Jones KW, Wei W, Stratton MR, et al. (2004). High-resolution analysis
of DNA copy number using oligonucleotide microarrays. Genome Res 14,
287–295.
[24] Dutt A and Beroukhim R (2007). Single nucleotide polymorphism array anal-
ysis of cancer. Curr Opin Oncol 19, 43–49.
[25] Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart
PM, and Montori VM (2008). The diagnosis of Cushing’s syndrome: an
Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93,
1526–1540.
[26] Fassnacht M, Beuschlein F, Quinkler M, and Petersenn S (2010). Arterial
hypertension and subclinical Cushing’s syndrome [in German]. MMW Fortschr
Med 152, 39–41.
[27] Cheung KJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, Cheung D,
Johnson NA, Mungall AJ, Telenius A, et al. (2010). High resolution analysis of
follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss
of heterozygosity and copy number alterations that target single genes. Genes
Chromosomes Cancer 49, 669–681.
[28] Choy KW, Setlur SR, Lee C, and Lau TK (2010). The impact of human copy
number variation on a new era of genetic testing. BJOG 117, 391–398.
[29] Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate—a
practical and powerful approach to multiple testing. J R Stat Soc B Met 57,
289–300.
[30] Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T,
Julien P, Roth A, Simonovic M, et al. (2009). STRING 8—a global view on
proteins and their functional interactions in 630 organisms. Nucleic Acids Res
37, D412–D416.
[31] Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P,
Doerks T, Stark M, Muller J, Bork P, et al. (2011). The STRING database
in 2011: functional interaction networks of proteins, globally integrated and
scored. Nucleic Acids Res 39, D561–D568.
[32] Haralambieva E, Kleiverda K, Mason DY, Schuuring E, and Kluin PM (2002).
Detection of three common translocation breakpoints in non–Hodgkin’s lym-
phomas by fluorescence in situ hybridization on routine paraffin-embedded tissue
sections. J Pathol 198, 163–170.
[33] LeBron C, Pal P, Brait M, Dasgupta S, Guerrero-Preston R, Looijenga LH,
Kowalski J, Netto G, and Hoque MO (2011). Genome-wide analysis of genetic
alterations in testicular primary seminoma using high resolution single nucleo-
tide polymorphism arrays. Genomics 97, 341–349.
[34] Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S,
Wuttig D, Wirth MP, and Baretton GB (2008). Loss of heterozygosity and
copy number abnormality in clear cell renal cell carcinoma discovered by
high-density Affymetrix 10K single nucleotide polymorphism mapping array.
Neoplasia 10, 634–642.
[35] Chari R, Coe BP, Vucic EA, Lockwood WW, and Lam WL (2010). An inte-
grative multi-dimensional genetic and epigenetic strategy to identify aberrant
genes and pathways in cancer. BMC Syst Biol 4, 67.
Neoplasia Vol. 14, No. 3, 2012 CNA and LOH in Adrenocortical Tumors Ronchi et al. 217
[36] Pfaffl MW (2001). A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res 29, e45.
[37] Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B,
Beuschlein F, Willenberg HS, Hahner S, et al. (2010). High diagnostic and
prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin
Endocrinol Metab 95, E161–E171.
[38] Lobry C, Oh P, and Aifantis I (2011). Oncogenic and tumor suppressor
functions of Notch in cancer: it’s NOTCH what you think. J Exp Med 208,
1931–1935.
[39] Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH,
Lerario AM, Maciel CC, Mattos GE, Jorge AA, et al. (2008). Expression of
insulin-like growth factor-II and its receptor in pediatric and adult adreno-
cortical tumors. J Clin Endocrinol Metab 93, 3524–3531.
[40] Yashiro T, Hara H, Fulton NC, Obara T, and Kaplan EL (1994). Point muta-
tions of ras genes in human adrenal cortical tumors: absence in adrenocortical
hyperplasia. World J Surg 18, 455–460; discussion 460-451.
[41] Patterson EE, Holloway AK, Weng J, Fojo T, and Kebebew E (2011). Micro-
RNA profiling of adrenocortical tumors reveals miR-483 as a marker of malig-
nancy. Cancer 117, 1630–1639.
[42] Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, Willscher E,
Walz MK, Worm K, and Schmid KW (2011). Differential expression of
microRNA-675, microRNA-139-3p and microRNA-335 in benign and malig-
nant adrenocortical tumours. J Clin Pathol 64, 529–535.
[43] Pasquale EB (2010). Eph receptors and ephrins in cancer: bidirectional signal-
ling and beyond. Nat Rev Cancer 10, 165–180.
[44] El Wakil A and Lalli E (2011). The Wnt/β-catenin pathway in adrenocortical
development and cancer. Mol Cell Endocrinol 332, 32–37.
[45] Artunc F, Sandulache D, Nasir O, Boini KM, Friedrich B, Beier N, Dicks E,
Potzsch S, Klingel K, Amann K, et al. (2008). Lack of the serum and
glucocorticoid-inducible kinase SGK1 attenuates the volume retention after
treatment with the PPARγ agonist pioglitazone. Pflugers Arch 456, 425–436.
[46] Amato R, D’Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C, Costa N,
Bellacchio E, Mattarocci S, Fuiano G, et al. (2009). Sgk1 activates MDM2-
dependent p53 degradation and affects cell proliferation, survival, and differen-
tiation. J Mol Med (Berl) 87, 1221–1239.
[47] Lang F, Perrotti N, and Stournaras C (2010). Colorectal carcinoma cells—
regulation of survival and growth by SGK1. Int J Biochem Cell Biol 42,
1571–1575.
[48] Reiter MH, Vila G, Knosp E, Baumgartner-Parzer SM, Wagner L, Stalla GK,
and Luger A (2011). Opposite effects of serum- and glucocorticoid-regulated
kinase-1 and glucocorticoids on POMC transcription and ACTH release. Am
J Physiol Endocrinol Metab 301, E336–E341.
[49] Miyata S, Koyama Y, Takemoto K, Yoshikawa K, Ishikawa T, Taniguchi M,
Inoue K, Aoki M, Hori O, Katayama T, et al. (2011). Plasma corticosterone
activates SGK1 and induces morphological changes in oligodendrocytes in
corpus callosum. PLoS One 6, e19859.
[50] Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, and Vallon V
(2006). (Patho)physiological significance of the serum- and glucocorticoid-
inducible kinase isoforms. Physiol Rev 86, 1151–1178.
[51] Tyybakinoja A, Elonen E, Vauhkonen H, Saarela J, and Knuutila S (2008).
Single nucleotide polymorphismmicroarray analysis of karyotypically normal acute
myeloid leukemia reveals frequent copy number neutral loss of heterozygosity.
Haematologica 93, 631–632.
[52] Hayward P, Brennan K, Sanders P, Balayo T, DasGupta R, Perrimon N, and
Martinez Arias A (2005). Notch modulates Wnt signalling by associating with
Armadillo/β-catenin and regulating its transcriptional activity. Development 132,
1819–1830.
[53] Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco
AJ, Herlyn M, and Liu ZJ (2005). Activation of Notch1 signaling is required
for β-catenin–mediated human primary melanoma progression. J Clin Invest
115, 3166–3176.
[54] Failor KL, Desyatnikov Y, Finger LA, and Firestone GL (2007). Glucocorticoid-
induced degradation of glycogen synthase kinase-3 protein is triggered by serum-
and glucocorticoid-induced protein kinase and Akt signaling and controls β-catenin
dynamics and tight junction formation in mammary epithelial tumor cells. Mol
Endocrinol 21, 2403–2415.
[55] Mo JS, Ann EJ, Yoon JH, Jung J, Choi YH, KimHY, Ahn JS, Kim SM, KimMY,
Hong JA, et al. (2011). Serum- and glucocorticoid-inducible kinase 1 (SGK1)
controls Notch1 signaling by downregulation of protein stability through Fbw7
ubiquitin ligase. J Cell Sci 124, 100–112.
218 CNA and LOH in Adrenocortical Tumors Ronchi et al. Neoplasia Vol. 14, No. 3, 2012
Figure W1. Chromosomal view of one representative chromosome (chr 1) in 15 cortisol-secreting ACA. The heat map shows the inten-
sity plots in each sample. Gains/amplifications are represented in red and losses/deletions in blue. The CN profile is shown for one
representative case (no. 312A). Normal CN score corresponds to 2.0, whereas gains correspond to a CN score greater than 2.5 and
losses to a CN score less than 1.5 in blue. The genomic segmentation (Partek GS) shows the altered regions for each sample (selected
case underlined). CN gains are represented in red and CN losses in blue.
Table W1. Primers for RT-qPCR at the DNA Level (Validation) and at the mRNA Level (Gene Expression) for the Candidate Genes and for the Internal Reference Genes.
DNA RT-qPCR
Gene Symbol Primers Chromosome
IGF2 fw 5′-gct gac acc tgg cgg cca tt-3′ 11
rw 5′-ggc gtc ctg act ttg ccc cc-3′
EPHA7 fw 5′-agg cct tgg cca gga agc tg-3′ 6
rw 5′-ggc ttg cac ata tcc ctt ctg ccc-3′
SGK1 fw 5′-tgg aag ctg ctg ctg ccc ac-3′ 6
rw 5′-tgt cca tct ctg gcc ccc gg-3′
CTNNB1 fw 5′-acg agg agg caa gtt tct cca agg-3′ 3
rw 5′-tgc gcc tct ccc cac ctc ac-3′
CYP11B2 fw 5′-cct gtg tct tgg ggc gg-3′ 8
rw 5′-ggc ctt ggg cga cag cac at-3′
GAPDH fw 5′-tga cgc tgg ggc tgg cat tg-3′ 12
rw 5′-ggc ggc aga ccc tgc act tt-3′
RNA RT-qPCR
Gene Symbol Primer Probe Mix* Chromosome Amplicon Length (bp)
IGF2 Hs00171254_m1 11 94
EPHA7 Hs01033009_m1 6 88
SGK1 Hs00178612_m1 6 81
CTNNB1 Hs00994404_g1 3 93
FHIT Hs00179987_m1 3 79
NOTCH1 Hs01062014_m1 9 80
CYP11B1 Hs01596404_m1 8 137
CYP11B2 Hs01597732_m1 8 137
HRAS Hs00610483_m1 11 69
β-actin Hs9999903_m1 7 171
*TaqMan Gene Expression Assays (Applied Biosystems).
Table W4. Gene Ontology Family Analysis (Performed with GSEA) Including the Genes with CNAs Observed in at Least 2 of 15 Cortisol-Secreting ACAs (Frequency,≥13%; Total, 638 Recognized Genes).
Cytokines and Growth Factors Transcriptional Factors Homeodomain Proteins Cell Differentiation Markers Protein Kinases Oncogenes Tumor Suppressor Genes
CTGF IRX4 IRX4 CD151 ADCK5 CTNNB1 FANCA
IGF2 LHX3 LHX3 CD24 BRSK2 DUX4 RECQL4
INS NKX6-2 NKX6-2 IFITM1 CAMK2B HRAS TSC2
INS-IGF2 TGIF1 TGIF1 IL9R CDK10 NOTCH1 FHIT
KITLG VENTX TGIF2LY L1CAM CDK11A PRDM16 H19
PDGFA CTNNB1 UNCX RHCE EPHA7 STIL
SCT DUX4 VENTX TNFRSF4 EPHB2
SLURP1 PRDM16 IRAK1
ARC MAPK15
DEAF1 NRBP2
E2F2 PRKCZ
E4F1 PRKG1
FAM20C PRKY
FOXH1 PTK2
HES4 SGK1
HES5
HEY2
HSF1
HSFY1
ID3
IRF7
LRRC14
MAFK
MECP2
MFSD3
NFKBIL2
NPAS2
PHRF1
PRDM7
RASSF7
REV3L
RXRA
SCRT1
SNAPC4
SOX8
SRY
TBL1Y
TP73
TRIP13
UTF1
ZFY
ZNF16
ZNF250
ZNF251
ZNF33B
ZNF696
ZNF7
Red: genes with CN gains
Blue: genes with CN losses.
Underlined: genes with microalterations.
Bold: genes altered in at least three samples (frequency, ≥20%).
Figure W2. The Notch signaling pathway map (A, gene ontology enrichment P = 1.494e−6) and the Wnt and Notch signaling in early
cardiac myogenesis (B, gene ontology enrichment, P = 4.287e−6) according to the GeneGo analysis (MetaCore Analytical suite) includ-
ing all the genes (n = 285 annotated genes) with CNAs observed in at least two samples (recurrent CNA). Genes with gains are under-
lined in red and genes with losses in blue. Detailed legend is available at http://www.genego.com/mapsearch.php.
Figure W3. The entire Notch signaling gene network according to the GeneGo analysis (MetaCore Analytical suite). Detailed legend is
available at http://www.genego.com/mapsearch.php.
Figure W4. Graphical representation of the STRING-generated protein-protein network (action view) for the single genes with CN micro-
alterations observed in at least two samples (n = 46 annotated genes). Modes of action are shown in different colors. Detailed legend is
available at http://string-db.org/newstring_cgi/show_network_section.
